<cite id="ffb66"></cite><cite id="ffb66"><track id="ffb66"></track></cite>
      <legend id="ffb66"><li id="ffb66"></li></legend>
      色婷婷久,激情色播,久久久无码专区,亚洲中文字幕av,国产成人A片,av无码免费,精品久久国产,99视频精品3
      網易首頁 > 網易號 > 正文 申請入駐

      “以光為刃”,當傳統工藝無解,藥明康德如何將新藥化學合成的鴻溝化為坦途?

      0
      分享至

      在新藥研發道路上,有時候決定成敗的往往不是宏大的敘事,而是一次關鍵化學中間體的高效合成。這類中間體如同精密的齒輪,其結構的細微偏差,都可能導致后續進程的停滯。在藥明康德的眾多客戶里,許多重要合作常常始于一個看似微小卻至關重要的化學工藝節點。

      故事要從一個棘手的分子骨架說起。

      某公司在推進一個極具潛力的分子項目時,被一個關鍵的“路障”卡住了。項目急需構建一個復雜而精確的三維分子骨架。這個骨架,是整個藥物分子的“心臟”,它的形狀、空間結構都必須分毫不差。因此,只有成功構建出正確立體構型的核心骨架,才能構建出具有生物活性的復雜分子,進而有望推進臨床,拯救生命。

      然而,擺在他們面前的,是行業內傳統分批工藝的“瓶頸”。

      傳統分批工藝生產模式是將所有原料按順序投入反應容器中,在設定好的溫度、壓力下攪拌、反應。待反應結束,再進行分離提純,得到產物。在這個項目中,如果采用傳統合成路線,需經過5步反應,效率較低。而且,最終得到的產物里,只有一半是符合要求的立體構型,整體收率也不高。

      更為棘手的是,傳統分批工藝從實驗室的克級探索放大到千克級生產時,橫亙著一條難以逾越的“鴻溝”。這不是簡單地把原料配方乘以1000就能解決的。規模放大后,反應體系的物理環境會發生變化,許多在燒瓶中運行良好的反應,一旦進入大釜,就可能面臨效率下降、甚至失敗風險。要解決這些挑戰,就需要耗費更多時間和資源來重新摸索工藝條件。

      面對難題,該公司第一時間聯系上藥明康德研發化學服務部(Research Chemistry Services,RCS)。這種信任并非憑空而來。它是十多年間,在多個合作項目里,由藥明康德一次次專業、高效的服務交付,一點一滴積累起來的。

      接到任務后,藥明康德RCS團隊迅速組建了由多個研發和生產基地專家構成的項目團隊,一場與時間賽跑的技術攻堅就此拉開序幕。

      如何破解分批工藝收率低、順反選擇性差,以及難以放大的“死結”?團隊的目光投向了光化學工藝技術。


      所謂光化學工藝,是利用特定波長的光能作為“精確的刻刀”,代替傳統的熱能或化學試劑,來精準切斷或重組化學鍵,從而高效構建目標分子。這聽起來似乎有些深奧,但光化學離我們的生活并不遙遠,就像晾在陽臺的彩色衣物,時間久了會慢慢褪色,其實是染料分子在太陽光的照射下發生了光化學反應;或是老式膠片相機按下快門的瞬間,膠片上的感光材料會因吸收光線而發生化學變化,最終定格下影像,也是光化學的典型應用。然而,當光化學技術應用于工業場景時,對設備、對人員的專業素養要求極高,它需要光能均勻、穩定地穿透反應體系,這在傳統的反應釜中幾乎無法實現。

      為此,項目團隊引入了一套高效的技術“組合拳”。

      首先登場的是高通量實驗(HTE),如果說分批工藝是在黑暗中一把把地嘗試“鑰匙”,那HTE就像同時啟動了上百個微型“智能鑰匙”,它能在極短時間內并行測試數百種反應條件——換一種光波長、試一種新催化劑、調一下濃度——過去需要幾周甚至幾個月的摸索,現在可將項目初期的摸索時間壓縮到以天計,從而迅速鎖定關鍵“配方”。

      但僅找到“配方”還不夠,關鍵是如何讓它穩定、高效地運轉起來,并適用于規模放大。于是,流動化學技術便登場亮相。

      想象一下,不再讓原料悶在反應容器里“不均勻光照”,而是將它們像輸液一樣,通過細細的管道持續泵入一個盤成線圈的透明“光隧道”。反應物一邊勻速流動,一邊接受管道外壁均勻的光照,真正實現了“邊走邊反應”。

      在這條精心設計的“光隧道”上,光照條件均勻穩定,反應路徑精準可控。原本需要5步、多批次投放、多次分離、轉移的復雜過程,如今像一條流水線,僅需1步連貫完成。

      結果是令人驚喜的——產物收率良好,順式選擇性極高。更難得的是,項目團隊僅用了9個小時,就完成了100克以上規模的精準制備,這意味著該工藝路線已成功跨越實驗室研究階段,具備了直接為后續毒理研究、臨床試驗提供足量藥物的能力,也為未來更大規模化生產奠定了堅實的技術基礎。這種效率與質量的雙重提升,使得原本預估需要4個多月的項目工期,被大幅縮短至僅10周。

      當項目團隊將高質量的產物交付到客戶手中時,客戶的項目負責人難掩興奮,高度贊賞道:“你們對光化學工藝的掌握和應用令人印象深刻,新的技術為我們打開了路線優化的大門,不僅提高了產量,也讓規模放大成為可能。”

      如今,這家客戶仍有多個后續項目與藥明康德持續合作。


      圖片來源:123RF

      這不僅是藥明康德光化學平臺一次高質量的服務交付,更是公司“讓天下沒有難做的藥,難治的病”這一愿景在微觀層面的生動注腳。這一成功的賦能案例,不僅彰顯了藥明康德在光化學領域的技術深度,更是公司全面化學能力的堅實印證,是公司CRDMO全球賦能平臺在創新浪潮中的一個典型縮影。

      回首二十余載,藥明康德構建的一體化、端到端CRDMO賦能平臺,早已超越了單純的技術疊加。公司將光化學、電化學、流動化學、酶催化等一系列創新技術融會貫通,以更好地賦能全球合作伙伴。因為,每一次分子的合成,背后都是滿懷期待的科學家和客戶,以及等待救治的患者。正是這份敬畏與擔當,驅動公司支持全球數千家合作伙伴破解研發挑戰,加速新藥從分子走向臨床的過程,讓創新療法突破瓶頸,推動更多新藥、好藥早日問世。

      Light and Flow: How WuXi AppTec Bridges the Gap in Novel Drug Chemical Synthesis

      In the journey of new drug development, success or failure often hinges on the efficient synthesis of a single, critical chemical intermediate—far more than on grand narratives. Among WuXi AppTec’s many customers, numerous significant collaborations begin at what may seem like a minor but is in fact a pivotal point in the chemical process.

      The story starts with a challenging molecular scaffold.

      A company was advancing a highly promising molecule when it hit a critical roadblock. The project urgently required the construction of a complex and precise three-dimensional molecular scaffold. This scaffold was the “heart” of the drug molecule; its shape and spatial structure had to be flawless. Therefore, successfully constructing this core scaffold with correct stereo configuration was the only way to build a biologically active complex molecule, ultimately advancing it toward clinical trials and the potential to save lives.

      However, the team faced a bottleneck inherent to traditional batch processing.

      In traditional batch processing, all raw materials are sequentially added to a reaction vessel, stirred, and reacted under set temperature and pressure conditions. Once the reaction is complete, the product is isolated and purified.For this project, the conventional synthetic route would have required five reaction steps, resulting in low efficiency. Moreover, only about half of the final product possessed the required stereo configuration, and the overall yield was low.

      An even greater challenge was the significant gap between gram-scale laboratory exploration and kilogram-scale production using traditional batch methods. This scaling-up process is not a simple matter of multiplying the recipe by a factor of 1000. When a process is scaled up, the physical environment of the reaction system changes. Many reactions that work smoothly in a flask may face decreased efficiency or even fail when transferred to a large reactor. Overcoming these challenges would require substantial additional time and resources to re-optimize the process conditions.

      Faced with this challenge, the company immediately contacted WuXi AppTec’s Research Chemistry Services (RCS) team. This trust was not built overnight. It has been accumulated over more than a decade through multiple collaborative projects, earned through consistent delivery of professional and efficient services.

      Upon receiving the task, the RCS team quickly pulled together experts from multiple sites—kicking off a race against time to tackle the technical challenge.

      How could they solve the intertwined problems of low yield, poor cis-trans selectivity, and the difficulty of scaling up the batch process? The team’s focus turned to photochemistry.


      Photochemistry uses light energy of a specific wavelength as a “precision chisel,” replacing traditional thermal energy or chemical reagents to precisely break or reform chemical bonds, efficiently constructing the target molecule.While this might sound complex, photochemistry is not far from our daily lives. For example, colored clothes left to dry on a balcony slowly fade over time because the dye molecules undergo photochemical reactions under sunlight. Similarly, when a vintage film camera shutter clicks, the photosensitive material on the film absorbs light and undergoes a chemical change, capturing the image—a classic application of photochemistry. However, applying photochemistry in an industrial setting demands highly specialized equipment and expertise. It requires the light energy to penetrate the reaction system uniformly and stably, a feat nearly impossible in traditional reaction vessels.

      To address this, the project team implemented a powerful combination of technologies.

      The first was High-Throughput Experimentation (HTE). If batch processing is like trying keys one by one in the dark, HTE is like activating hundreds of miniature “smart keys” simultaneously. It allows hundreds of reaction conditions—varying the light wavelength, trying a new catalyst, adjusting the concentration—to be tested in parallel within a very short time. What used to take weeks or even months of exploration could now be compressed into days, enabling the team to rapidly lock in a critical “formula.”

      But finding the formula was only half the battle. The key was to make it run stably, efficiently, and in a scalable manner. This is where flow chemistry came into play.

      Imagine, instead of having the raw materials confined in a reactor with uneven light exposure, they were continuously pumped like an intravenous drip through a narrow tube coiled into a transparent “light tunnel.” As the reactants flowed at a constant rate, they received uniform illumination from the outside of the tube wall, truly achieving “reaction on the go.”

      Within this precisely engineered “light tunnel,” the light exposure was consistent and stable, and the reaction pathway was precisely controlled.The original complex process requiring five steps, multiple batch additions, and multiple separations and transfers was streamlined like an assembly line, completed in continuous flow in one step.

      The results were remarkable: excellent product yield, exceptionally high cis-selectivity, andprecise preparation of over 100 grams in just nine hours. This demonstrated that the process had successfully crossed the laboratory research stage, enabling the possibility to directly supply sufficient quantity of the drug candidate for subsequent toxicology studies and clinical trials, and laying a solid technical foundation for future large-scale production.This dual improvement in efficiency and quality shortened the project timeline significantly, from an estimated over four months to just ten weeks.

      When the project team delivered the high-quality product to the client, the client’s project lead couldn’t hide their excitement. "The photochemical process had opened the door to route optimization for us, not only increasing yield but also making it possible to scale-up."

      Since then, this client has continued to collaborate with WuXi AppTec on multiple subsequent projects.


      Image source: 123RF

      This case represents more than just a high-quality service delivery by WuXi AppTec’s photochemistry platform; it is a tangible microcosm of the company’s vision: “Every drug can be made, and every disease can be treated.” This successful enabling story not only highlights WuXi AppTec’s technical depth in the field of photochemistry but also stands as a solid testament to its comprehensive chemistry capabilities, serving as a quintessential example of its global CRDMO enabling platform in action amidst a wave of innovation.

      Looking back over more than two decades, WuXi AppTec’s integrated, end-to-end CRDMO enabling platform has gone beyond a mere collection of technologies. The company has integrated and mastered a suite of innovative technologies—including photochemistry, electrochemistry, flow chemistry, enzymatic catalysis, and beyond—to better enable its global partners. Behind every synthesis of a molecule, what we see are scientists and clients full of anticipation, as well as patients waiting for treatment. It is this sense of respect and responsibility that drives the company to support thousands of customers worldwide in tackling R&D challenges, accelerating the journey of new drugs from molecule to clinical, breaking through bottlenecks in innovative therapies, and helping bring more new and better medicines to patients faster.

      免責聲明:本文僅作信息交流之目的,文中觀點不代表藥明康德立場,亦不代表藥明康德支持或反對文中觀點。本文也不是治療方案推薦。如需獲得治療方案指導,請前往正規醫院就診。

      版權說明:歡迎個人轉發至朋友圈,謝絕媒體或機構未經授權以任何形式轉載至其他平臺。轉載授權請在「藥明康德」微信公眾號回復“轉載”,獲取轉載須知。

      特別聲明:以上內容(如有圖片或視頻亦包括在內)為自媒體平臺“網易號”用戶上傳并發布,本平臺僅提供信息存儲服務。

      Notice: The content above (including the pictures and videos if any) is uploaded and posted by a user of NetEase Hao, which is a social media platform and only provides information storage services.

      相關推薦
      熱點推薦
      小米新車突然發布,這配置也太夸張了!

      小米新車突然發布,這配置也太夸張了!

      XCiOS俱樂部
      2026-04-24 10:46:06
      哈里王子罕見表態:堅稱永遠是王室的一部分,查爾斯國王感到不滿

      哈里王子罕見表態:堅稱永遠是王室的一部分,查爾斯國王感到不滿

      人物檔案局
      2026-04-25 08:09:41
      100 日元兌 4.33 元:日本用三十年,把自己熬成了 “廉價國家”

      100 日元兌 4.33 元:日本用三十年,把自己熬成了 “廉價國家”

      深析古今
      2026-03-31 10:10:57
      扎心了!21歲大一女生月開銷曝光!網友驚問:畢業后能掙這么多嗎

      扎心了!21歲大一女生月開銷曝光!網友驚問:畢業后能掙這么多嗎

      慧翔百科
      2026-04-24 08:58:31
      好消息!東西城“最火駐京辦”重新開業了!

      好消息!東西城“最火駐京辦”重新開業了!

      東西城早知道
      2026-04-24 17:43:10
      高市施壓讓步,3支代表團要求訪華,中國"4箭齊發",日本強烈抗議

      高市施壓讓步,3支代表團要求訪華,中國"4箭齊發",日本強烈抗議

      田柳
      2026-04-25 09:00:09
      數據:丁俊暉長臺成功率僅33%亟待提升,出桿速度比趙心童慢很多

      數據:丁俊暉長臺成功率僅33%亟待提升,出桿速度比趙心童慢很多

      楊華評論
      2026-04-25 04:57:02
      別再被儀表盤騙了!高速表顯120,實際車速差很多,很多司機不懂

      別再被儀表盤騙了!高速表顯120,實際車速差很多,很多司機不懂

      周哥一影視
      2026-04-24 13:34:49
      光通信行業迎來新變局,2026年潛力龍頭值得關注

      光通信行業迎來新變局,2026年潛力龍頭值得關注

      普陀動物世界
      2026-04-24 20:40:24
      繼人民日報發聲后,官媒再次三問董宇輝,言辭犀利,字字揭他老底

      繼人民日報發聲后,官媒再次三問董宇輝,言辭犀利,字字揭他老底

      離離言幾許
      2026-04-23 20:04:00
      小姨子喬遷宴嫌我窮,拒我參加,我沒鬧,次日見150個未接來電

      小姨子喬遷宴嫌我窮,拒我參加,我沒鬧,次日見150個未接來電

      麥子情感故事
      2026-04-24 16:12:08
      特朗普再立奇功!北約成立77年以來首次:美國拜拜,不帶你玩了

      特朗普再立奇功!北約成立77年以來首次:美國拜拜,不帶你玩了

      軍聞新大門
      2026-04-25 02:28:20
      天津小區名有多離譜?本地人笑噴,外地人看懵

      天津小區名有多離譜?本地人笑噴,外地人看懵

      音樂時光的娛樂
      2026-04-25 03:52:59
      創4項CBA歷史最差!四川遭浙江橫掃本季42戰全敗 跨賽季47連敗

      創4項CBA歷史最差!四川遭浙江橫掃本季42戰全敗 跨賽季47連敗

      醉臥浮生
      2026-04-24 21:00:39
      北京大學教授喬曉春言論惹爭議,我們應該上綱上線嗎?

      北京大學教授喬曉春言論惹爭議,我們應該上綱上線嗎?

      總在茶余后
      2026-04-22 21:14:14
      “高度贊賞中方的領導作用,投入了真金白銀”

      “高度贊賞中方的領導作用,投入了真金白銀”

      觀察者網
      2026-04-24 22:14:34
      46歲小李琳復出拍戲,姐弟戀真實狀況引關注

      46歲小李琳復出拍戲,姐弟戀真實狀況引關注

      枯蝶
      2026-04-24 08:03:05
      146年來,全球僅有120位醫生獲得的殊榮,瑞金這位醫生拿到了!

      146年來,全球僅有120位醫生獲得的殊榮,瑞金這位醫生拿到了!

      上海交通大學醫學院附屬瑞金醫院
      2026-04-24 18:55:17
      網友稱用豆包提前查到事業編成績,官方回應:工作人員在測試成績查詢端口的時候,有網民無意中點進去了,沒有造成什么不良影響

      網友稱用豆包提前查到事業編成績,官方回應:工作人員在測試成績查詢端口的時候,有網民無意中點進去了,沒有造成什么不良影響

      都市快報橙柿互動
      2026-04-24 18:14:20
      78歲港星窮到1000塊都沒,曾拿400多萬幫女兒還債,而今還被拋棄

      78歲港星窮到1000塊都沒,曾拿400多萬幫女兒還債,而今還被拋棄

      草莓解說體育
      2026-04-25 09:06:38
      2026-04-25 09:39:00
      醫學新視點 incentive-icons
      醫學新視點
      關注醫療健康的最新發展
      4972文章數 31266關注度
      往期回顧 全部

      科技要聞

      DeepSeek V4牽手華為,價格依然"屠夫級"

      頭條要聞

      聲稱考慮效仿伊朗在馬六甲收"過路費"后 印尼財長改口

      頭條要聞

      聲稱考慮效仿伊朗在馬六甲收"過路費"后 印尼財長改口

      體育要聞

      上海男籃23連勝+主場全勝 姚明之后最強一季

      娛樂要聞

      鄧超最大的幸運,就是遇見孫儷

      財經要聞

      別高估英偉達,別低估DeepSeek

      汽車要聞

      2026款樂道L90亮相北京車展 樂道L80正式官宣

      態度原創

      手機
      本地
      房產
      家居
      公開課

      手機要聞

      全面回歸OPPO!realme真我商城明日起停止運營

      本地新聞

      云游中國|逛世界風箏都 留學生探秘中國傳統文化

      房產要聞

      新一輪教育大爆發來了!海口,開始瘋狂建學校!

      家居要聞

      自然肌理 溫潤美學

      公開課

      李玫瑾:為什么性格比能力更重要?

      無障礙瀏覽 進入關懷版 主站蜘蛛池模板: 国产又爽又黄又刺激的视频| 亚洲av成人在线| 亚洲国产精品色一区二区| 香蕉视频在线观看黄| 色噜噜人妻丝袜AⅤ资源| 东京热无码av男人的天堂| 日韩人妻无码精品系列| 国产乱人伦| 爆乳2把你榨干哦ova在线观看| 少妇人妻av无码专区| 国产激情久久久久久熟女老人av| 在线v片免费观看视频| 亚洲精品一区二区三区新线路 | 国产成人夜色高潮福利影视| 日韩精品一区二区三区视频| 国产午夜在线观看视频播放| 亚洲精品岛国片在线观看| 天天艹天天干| 亚洲第一网站| 西西大胆午夜人体视频| 色妞色综合久久夜夜| 久久久一本波多野结衣| 综合久久国产九一剧情麻豆| 狠狠cao日日穞夜夜穞av| 欧美一区二区三区久久综合 | 国产三级精品三级男人的天堂,| 99精品电影一区二区免费看| 国产精品后入内射视频| 老熟妇性老熟妇性色| 日本特黄特黄刺激大片| 国产无码AV| 人妻久久久一区二区三区| 欧美视频精品| 1024国产视频| www夜插内射视频网站| 女人夜夜春高潮爽a∨片传媒| 精品一区二区三区波多野结衣| 少妇放荡的呻吟干柴烈火动漫| 人妻无码久久一区二区三区免费| 国产jizzjizz视频| 狼友福利网|